Histogenics Corporation (HSGX) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Histogenics Corporation (NASDAQ:HSGX) from a hold rating to a buy rating in a research report released on Wednesday morning. Zacks Investment Research currently has $2.25 target price on the biotechnology company’s stock.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
A number of other research firms have also weighed in on HSGX. Canaccord Genuity reaffirmed a buy rating and issued a $4.00 price objective on shares of Histogenics Corporation in a research note on Friday, August 11th. HC Wainwright reaffirmed a buy rating and issued a $3.50 price objective on shares of Histogenics Corporation in a research note on Thursday, November 2nd. Finally, ValuEngine lowered shares of Histogenics Corporation from a sell rating to a strong sell rating in a research note on Monday, August 14th.
Histogenics Corporation (NASDAQ:HSGX) traded up $0.06 during trading on Wednesday, hitting $1.91. 12,598 shares of the company’s stock were exchanged, compared to its average volume of 111,962. Histogenics Corporation has a 12-month low of $1.45 and a 12-month high of $2.40.
Histogenics Corporation (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. equities research analysts anticipate that Histogenics Corporation will post -1.07 EPS for the current fiscal year.
Histogenics Corporation Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.